NFE2L2 and colorectal carcinoma: Regarding NFE2L2, CLytA-DAAO treatment would not be a problem either in pancreatic or colorectal carcinoma, however, in a percentage of glioblastoma patients, the expression level of these genes suggests a putative resistance to CLytA-DAAO treatment.